• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

Relesys: A mixed bag, but with a few more negatives - ABG

Relesys

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
DKK 51.8m ARR ~3% below ABGSCe, 17% adj. EBITDA beat
Limited ARR estimate revisions, '24e-'25e adj. EBITDA cut 1-6%
FVR of DKK 3.2-8.5


Limited '23e-'25e ARR revisions despite weaker Q2 DARR

We make minor revisions to '23e-'25e ARR (<1%) and continue to expect FY'23e ARR around the mid-point of the reiterated DKK 59m-64m guidance despite Q2 q-o-q DARR of DKK 2.4m being a tad to the weak side. Q2 ARR of DKK 51.8m (36% y-o-y growth) was ~3% below our estimate, with the miss driven by substantially lower y-o-y ARR uplift at 15% vs. ABGSCe at 20%; churn at ~3% was slightly better and new ARR of 24% was largely in line with our estimates. Management admits it has not landed enough deals in Q2 (which follows an impressive Q1 where it landed the large grocery wholesaler NorgesGruppen), but claims it sees no change in demand since Q1. H1 revenues of DKK 26.7m were directly in line with our estimate, but we lower '23e-'25e revenues by 1-2% on lower consultancy revenues.